EHVVF: From Dormant OTC To AI Deals And Product Launches
- Checkers
- Jun 10
- 3 min read
For much of the past few years Ehave Inc. (OTC PINK: $EHVVF) was buried on EM with delinquent filings. That changed in December last year when the company regained compliance and returned to Pink Current status. In just 6 months, they are showing us what leadership with a plan looks like, clearly laying out (and executing on) their long-term vision as an AI-first incubator focused on artificial intelligence software, consumer robotics, and enterprise automation.
EHVVF’s moves showed concrete traction early this month when the company
closed a $10 million acquisition of AIHeadHunter, an AI-driven executive recruitment platform. The transaction included $2.7 million in Series A convertible preferred stock and 100 million common shares issued to Klizo Ventures, now a major shareholder.
AIHeadHunter automates recruiting through natural language processing and machine learning to source, screen, and rank candidates, reducing both time-to-hire and cost-per-hire for enterprise customers. The platform operates under AI infrastructure veteran Joey Ricard and is targeting Q3 2025 for its SaaS platform launch with initial enterprise pilots and subscription revenue goals. The company is preparing a Regulation A raise to fund the rollout.
Parallel to this software initiative, EHVVF is advancing consumer robotics through majority-owned subsidiary AIBotics, Inc. (OTC PINK: $AIBT). AIBotics' flagship product, the Phill Robot, is billed as the world's first AI-powered bedside massage robot. The device features a patented foldable robotic arm capable of applying up to 15 pounds of force for massage treatments.
The strong early demand for Phill Robot was validated with an Indiegogo campaign that surpassed its funding goal by over 300%, established a waitlist for the product, and gained mainstream media coverage. The company has also signed UI/UX development agreements to finalize the consumer interface. Commercial launch is planned for Q2 2025, with pilot deployments already in motion at a Miami wellness center.
Beyond these flagship products, EHVVF continues incubating additional AI initiatives. AI BioLab explores integrating generative biology with cloud robotics to automate laboratory workflows in life sciences research, while AI HealthOps aims to leverage large language models for streamlining healthcare operations like claims processing and billing. Both remain in development with no commercial products released (yet).
Upcoming catalysts will now test whether EHVVF can translate its AI-first vision into measurable commercial progress. These include efforts to uplist to OTCQB, converting initial Phill Robot deployments into revenue, advancing AIHeadHunter from pilot stage to paid subscriptions, and the potential closing of a $40 million acquisition of AI-powered music technology firm DigiTrax by the company’s subsidiary AIBT.
The transformation from regulatory cleanup to aggressive AI repositioning represents an unusual post-EM development surge, backed by real acquisitions, tangible products, and visible execution milestones. The next six to nine months will be crucial to watch for signs the AI-first strategy can deliver on the company's applied artificial intelligence ambitions.
Disclaimer: The information provided here is not intended to be a comprehensive analysis of the subjects mentioned. All information, opinions, and forecasts contained herein should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities or related financial instruments. Investors should conduct their own research or consult with a qualified financial advisor before making any investment decisions. The author and publisher of this content are not responsible for any losses, damages, or other consequences that may result from the use of the information provided. Investing in stocks, including those mentioned here, involves risks, including the risk of loss.
